Latest news for Thermador Groupe (OTC:THEPF) Stock

Thermador Groupe SA is engaged in the distribution of materials for the circulation of fluids in the building, public works and industry. It involves the distribution of accessories for heating and domestic hot water, heating pumps, plumbing equipment, sanitary taps, building taps, ventilation, industrial taps, cold water pumps, plastic pipes (ducts, tubes, drains, fittings, etc.) for wet and dry networks, construction, public works and irrigation, swimming pool equipment and accessories, air compressors, generators and welding sets.

THERMADOR GROUPE SA by Thermador Groupe SA

Thermador Groupe SA

Truist Securities analyst David Smith initiates coverage on Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Buy rating and announces Price Target of $91.

News

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Bank of New York Mellon with Buy Rating, Announces Price Target of $91

Health Care

General

OraSure's OraQuick HIV Self-Test Gets Approval For Use In Adolescents

<ul>
<li>Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025</li>
<li>Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile</li>
<li>Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing</li>
</ul>

Biotech

MBX Biosciences Announced Results From Its Phase 1 Single Ascending Dose And Multiple Ascending Dose Trial Of MBX 1416 In Healthy Adult Volunteers. The Company Is Developing MBX 1416 For Post-bariatric Hypoglycemia

JP Morgan analyst Jimmy Bhullar downgrades Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) from Overweight to Neutral and raises the price target from $74 to $79.

Downgrades

JP Morgan Downgrades Unum Gr to Neutral, Raises Price Target to $79

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway -
- Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) -
- Encouraging initial data for IMM-1-104&nbsp;monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled across all three Phase 2a pancreatic arms -
- Continued highly differentiated tolerability profile observed for IMM-1-104; approved MEK inhibitors currently drive ~$2.4 billion in sales -
- Further IMM-1-104 Phase 2a data expected in 2Q'25; additional combination arms planned to be initiated in 2025 -

Immuneering Reveals Data From Three Pancreatic Cancer Arms In Phase 2a Trial Of IMM-1-104; Announces Plans For Trial Expansion With Additional Arms

Keybanc analyst Matthew Gillmor upgrades Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announces $70 price target.

Upgrades

ACHC

Keybanc Upgrades Acadia Healthcare Co to Overweight, Announces $70 Price Target

This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&amp;D Systems branded TIGIT and CCR-7 antibodies. &nbsp;

Legal

TECH

Bio-Techne Announced That It Prevailed On Another Claim That Miltenyi Biotec Commercialized Antibodies Developed Based On Information Obtained By Reverse Engineering Bio-Techne's Proprietary R&D Systems Branded NKG2C/CD159c Antibodies

BABA

BBAI

BFRG

BIDU

GFAI

GOOG

GOOGL

INTC

INTU

LPSN

MARK

MCHX

MSFT

NVDA

QCOM

SNAP

SOUN

SSTK

TBLA

VERI

Software IP Licensor Ceva Says Its NeuPro-Nano Embedded AI NPUs Gain Traction In AIoT And MCU Markets

PERF

Perfect Corp. Partners With MAISON DELAROM To Launch AI-Driven Personalized Skincare at Maison & Objet 2025

Vertex will utilize Orna's novel and proprietary LNP delivery solutions to enhance efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
Under the terms of the agreement, Orna will receive upfront payments of $65 million, including an investment in the form of a convertible note, and is eligible to receive up to $635 million based upon the achievement of specified pre-clinical, research, development, regulatory and commercial milestones related to SCD/TDT products.
Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.&nbsp;

Contracts

VRTX

Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals;  Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones

<a href="https://www.bloomberg.com/news/articles/2025-01-07/russia-says-it-cut-crude-oil-output-below-opec-target-in-december" title="https://www.bloomberg.com/news/articles/2025-01-07/russia-says-it-cut-crude-oil-output-below-opec-target-in-december">https://www.bloomberg.com/news/articles/2025-01-07/russia-says-it-cut-crude-oil-output-below-opec-target-in-december</a>

Futures

Commodities

Markets

Bloomberg Reported Russia Says It Cut Crude Oil Output Below OPEC+ Target In December

On Monday, January 6th, U.S. markets closed mixed; the S&amp;P 500 and Nasdaq Composite climbed to over a week&#8217;s high, driven by semiconductor gains and optimism about a softer tariff approach under the Trump administration. The Dow edged lower while tech stocks rallied sharply. Investors monitored Federal Reserve cues and Trump&#8217;s potential economic impact.
According to economic data, in November, U.S. durable goods and factory orders fell by 0.4%, slightly below estimates and prior gains. December&#8217;s S&amp;P Global Services PMI dropped to 56.8, below forecasts, while the Composite PMI softened to 55.4, though both remained above their previous readings.
While seven out of the eleven S&amp;P 500 sectors declined, communication services and technology stocks rose significantly.
The Dow Jones Industrial Average was down 0.06% and closed at 42,706.56, the S&amp;P 500 closed higher by 0.55% at 5,975.40, while the Nasdaq Composite rose 1.24% to finish at 19,864.98.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 closed higher by 2.14% at 40,077.00, led by gains in the Mining, Power, and Chemical, Petroleum, and plastic sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.34%, ending the session at 8,285.10, led by gains in the IT, Telecoms Services, and Consumer Discretionary sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.32% at 23,691.40, and the Nifty 500 rose 0.46%, closing at 22,327.80. Gains in the Oil and gas, Capital Goods, and Metals sectors led the index.</li>
<li>China&#8217;s Shanghai Composite was up 0.71% and closed at 3,229.64, and the Shenzhen CSI 300 gained 0.72%, finishing the day at 3,796.11.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session lower by 1.22% at 19,447.58.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.47%.</li>
<li>Germany&#8217;s DAX gained 0.32%.</li>
<li>France&#8217;s CAC rose 0.54%.</li>
<li>U.K.&#8217;s FTSE 100 traded lower by 0.22%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.38% at $73.84/bbl, and Brent was up 0.59% at $76.75/bbl.</li>
<li>Oil prices dipped as optimism over demand waned amid weak global economic data, though tighter Russian and Iranian supply and increased heating oil demand due to cold weather limited further losses.</li>
<li>Natural Gas declined 4.30% to $3.514.</li>
<li>Gold was trading higher by 0.30% at $2,655.51, Silver was up 0.74% to $30.810, and Copper rose 0.84% to $4.1960.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.08%, S&amp;P 500 futures gained 0.10%, and Nasdaq 100 futures rose 0.09%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index was down 0.24% to 109.98, USD/JPY rose 0.10% to 157.75, and USD/AUD slid 0.59% to 1.5914.</li>
<li>The U.S. dollar eased toward a one-week low as traders speculated on a softer tariff stance from President-elect Trump, despite his denial of recent report.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Ex-Hong Kong Up, Europe Mixed; Dollar Hovers Near High - Global Markets Today While Us Slept

Following successful interactions with the FDA, EMA and PMDA, the Company has finalized its EMPEROR Phase 3 study protocol. The proposed study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg over 52-weeks compared to sham in children and adolescents ages 2 to &lt;18 with Dravet syndrome. The primary endpoint will be reduction in major motor seizure frequency. Key secondary endpoints will include improvements in cognition and behavior as measured primarily by Vineland-3. The Company plans to initiate the Phase 3 study in mid-2025.&nbsp;

STOK

Stoke Therapeutics Announced Alignment With Global Regulatory Agencies On The Design Of Its Phase 3 EMPEROR Study Of Zorevunersen For Dravet Syndrome, The Study Is Expected To Start In Mid-2025

Management

Lithium Americas Appoints Luke Colton As Finance Chief

Raymond James analyst Matt Roberts initiates coverage on AptarGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) with a Outperform rating and announces Price Target of $200.

Raymond James Initiates Coverage On AptarGroup with Outperform Rating, Announces Price Target of $200

Lithium Americas Increases Mineral Resource And Reserve For Thacker Pass

Needham analyst Joshua Reilly initiates coverage on AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) with a Buy rating and announces Price Target of $25.

AEYE

Needham Initiates Coverage On AudioEye with Buy Rating, Announces Price Target of $25

4 analysts have expressed a variety of opinions on Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Hudson Pacific Properties, revealing an average target of $3.88, a high estimate of $5.00, and a low estimate of $3.00. Observing a downward trend, the current average is 19.17% lower than the prior average price target of $4.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1736251252_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Hudson Pacific Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$3.70</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hudson Pacific Properties. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hudson Pacific Properties compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hudson Pacific Properties's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Hudson Pacific Properties's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HPP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hudson Pacific Properties analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Hudson Pacific Properties Better</h2>
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties &amp; related operations; and studio properties &amp; related operations. The majority of revenue is derived from the office properties &amp; related operations segment.
<h3>Financial Insights: Hudson Pacific Properties</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Hudson Pacific Properties's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -13.42%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Hudson Pacific Properties's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -48.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hudson Pacific Properties's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.69%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Hudson Pacific Properties's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.17%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Hudson Pacific Properties's debt-to-equity ratio stands notably higher than the industry average, reaching 1.76. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Hudson Pacific Properties

Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has been analyzed by 27 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $37.04, a high estimate of $55.00, and a low estimate of $21.00. Witnessing a positive shift, the current average has risen by 31.67% from the previous average price target of $28.13.
<img src="https://www.benzinga.com/files/images/story/2025/1736251244_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Robinhood Markets by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mahika Sapra</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Robinhood Markets. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Robinhood Markets compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Robinhood Markets's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Robinhood Markets's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Robinhood Markets analyst ratings.</a>
<h2>About Robinhood Markets</h2>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
<h3>Breaking Down Robinhood Markets's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Robinhood Markets's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 36.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Robinhood Markets's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Robinhood Markets's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.09%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Robinhood Markets's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.35%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Robinhood Markets's debt-to-equity ratio is below the industry average at 1.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HOOD

Robinhood Markets Stock: A Deep Dive Into Analyst Perspectives (27 Ratings)

In the latest quarter, 10 analysts provided ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated P10 and provided 12-month price targets. The average target is $14.4, accompanied by a high estimate of $21.00 and a low estimate of $12.00. Surpassing the previous average price target of $12.60, the current average has increased by 14.29%.
<img src="https://www.benzinga.com/files/images/story/2025/1736251236_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of P10 among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to P10. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of P10 compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of P10's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of P10's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on P10 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering P10: A Closer Look</h2>
P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
<h3>A Deep Dive into P10's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: P10's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 25.96%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: P10's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): P10's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.4%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): P10's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: P10's debt-to-equity ratio is below the industry average. With a ratio of 0.96, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Thermador Groupe

News

Latest news for Thermador Groupe (OTC:THEPF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga